Wed, Sep 17, 2014, 9:41 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

frenzychess 17 posts  |  Last Activity: Aug 28, 2014 1:51 PM Member since: Sep 3, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by frenzychess Aug 26, 2014 11:47 PM
    frenzychess frenzychess Aug 28, 2014 1:51 PM Flag

    The funniest post I've seen. Yes, it doesn't matter what % if you take milk!! Like saying you can take whatever amount of LSD you want, just drink milk with it and dilute the % down to nothing. No hallucinations there. Now that's science. You should be working with the FDA!

  • Reply to


    by frenzychess Aug 26, 2014 11:47 PM
    frenzychess frenzychess Aug 27, 2014 12:10 PM Flag

    Thanks. Yes, there are other ways to obtain pure EPA. However, for most people in the US, the advice they take to care for their health comes from their doctors. When their doctors prescribe Niaspan, Tricor or Lovaza that's what they take. I can talk until I'm blue in the face but I've had no success getting people I care about to use pure EPA. I don't blame those people, nor do I place much of the blame on their doctors. The FDA is the culprit here.

  • frenzychess by frenzychess Aug 26, 2014 11:47 PM Flag

    Approve this for the ANCHOR population already. This belongs in the category of FDA gone evil. I believe that some on that deciding panel deserve prison sentences for the harm they've done. It's personal now as I can never be as convincing as the "wonderful" doctors who will not listen to any of the Vascepa hubabaloo. I have a family member now with afib and a friend with several health issues resulting from high triglycerides. Still, neither can convince their doctor to prescribe Vascepa. Why? Because GSK needs to make money and apparently they scratch the backs of those who would abandon their "do no harm" vows, so doctors don't have the go ahead they need to prescribe this miracle capsule.

  • frenzychess by frenzychess Aug 16, 2014 11:38 AM Flag

    Reading the most recent scripts versus Niaspan, it shows that Niaspan NEW FRICKIN' SCRIPTS are higher than Vascepa. Really, you don't have to say anything more than that. The FDA is shameless, but doctors should be embarrassed.

  • Reply to

    Niaspan and Tricor

    by frenzychess Aug 10, 2014 9:42 AM
    frenzychess frenzychess Aug 13, 2014 12:52 AM Flag

    Hey Akanz! How do like taking Vascepa after all this time? I like your notes. I find it amusing that the FDA rushed into approve Niaspan, Tricor, all the other fibrates... without much proof that they did much, (just moved the markers). Vascepa, the one drug that does actually do something gets the back of the hand.

  • frenzychess by frenzychess Aug 10, 2014 9:42 AM Flag

    Billions and billions sold to .... do not a whole lot. Of course, if your triglyceride levels are way too high, any triglyceride reducing agent is preferable to nothing. So Niaspan and Tricor do help those folks. Vascepa helps more, reducing triglycerides while reducing inflammation and creating a vast array of ancillary benefits neither Niaspan nor Tricor will ever produce. Out of the three, Niaspan, Tricor and Vascepa; it is only Vascepa that has a trial, JELIS, showing a reduction in adverse heart events in patients with slightly elevated triglycerides. Vascepa has the added benefit of nearly zero side effects. So, the FDA is keeping a tight lid on Vascepa because it is too complex, yep, it's a real mystery. Good going FDA, so go approve the next VIOXX because big companies like MERCK are okay to let kill people for a while. After all, the billions in sales more than pay for the lawsuits to follow.

  • Reply to


    by frenzychess Aug 8, 2014 8:38 AM
    frenzychess frenzychess Aug 8, 2014 9:46 AM Flag

    Are you referring to the anecdotal JELIS study and the anecdotal ANCHOR study? Or, the anecdotal way AMRN set up the study to comply with all FDA requirements? Maybe you're referring to all the recent anecdotal study showing a definitive link between slightly elevated triglycerides and heart disease. The anecdotal Japanese study for hemodialysis patients shows that thousands have died anecdotally since the FDA sees the evidence for Vascepa as too complex. When REDUCE-IT does come out with its life saving anecdotes, that probably will also be too complex for the FDA. The simple thing is, giving AMRN ANCHOR will cost big pharma billions, and that's not according to the FDA playbook. Yes, they'll say no, I do agree.

  • frenzychess by frenzychess Aug 8, 2014 8:38 AM Flag

    Oh my! Jenkins says the issue is complex. That's a little bit like saying that water is complex. Yes, of course it is if you want to go to the sub atomic level and look for the god particle. Here it is...anyone with elevated triglycerides is looking at the number one killer in the world right in the eye and Vascepa reduces the risk more than any other agent without side effects, with the side benefits of reducing cancer risk, improving mood and healing joint pain. That's how complex this is.

  • frenzychess by frenzychess Aug 5, 2014 9:28 AM Flag

    Of course there is nothing quite like Vascepa for curing what ails you, yet the FDA keeps to its dogged dogma. We have a decision coming up shortly and I'm fairly certain I know the result. No dice! To give into Amarin would hurt several larger pharmaceutical companies and that's not in the cards it would seem. Reading the updated literature now on the topic of pure EPA, it makes me very sad to know for certain the FDA is rigged by money and corruption. ONLY a renewed SPA could possibly slightly renew my faith in this agency, yet I'm not holding my breath. By the way, if you or anyone you know is suffering from elevated triglycerides...take some Vascepa. Even if you have to knock your doctor upside the head to get a prescription, they are part of this hypocrisy even if they don't know they are compromising your health.

  • frenzychess by frenzychess Jul 18, 2014 2:05 PM Flag

    Shares fell off about 15% once it was learned the CEO Leif had sold 40% of his shares, (not all that many shares and a pre-planned sale, gheesh). Shares hit again by Janet Yellen saying biotech valuations were stretched. Neither event has much to do with what is likely to happen with ARNA. Since then ARNA has seen the sales force for Belviq raised from 400-600 reps and a re-launched add campaign that is packing a punch and is all the place right now. Scripts were way up this morning and likely to increase dramatically over just the next few weeks. An approved patent that bodes well for the future also gets thrown into the mix. Now the stock sits below $5 on misinterpreted information. It's easy, buy the heck out of this company.

    Sentiment: Strong Buy

  • frenzychess by frenzychess Jul 18, 2014 12:37 PM Flag

    Like watching an ant holding back a bowling ball.

    Sentiment: Strong Buy

  • Reply to

    Breaking Point?

    by frenzychess Jul 18, 2014 11:48 AM
    frenzychess frenzychess Jul 18, 2014 12:07 PM Flag

    Clearly the pricing is not reflecting the interest today. It just appears like there's a whole lot of buying interest and if it overwhelms these sellers look out, this is headed way up.

    Sentiment: Strong Buy

  • frenzychess by frenzychess Jul 18, 2014 11:48 AM Flag

    Level II showing an increasing supply of buyers as volume slows, looks like that will break here soon. A few sellers holding this tidal wave back right now. Perhaps the scripts data is pushing this. Looks like a tremendous opportunity to get into ARNA as an artificial barrier is about to break.

    Sentiment: Strong Buy

  • frenzychess by frenzychess Jul 18, 2014 10:36 AM Flag

    Huge volume I'm seeing...what's happening? Looks like this could explode.

  • frenzychess by frenzychess Jul 18, 2014 10:10 AM Flag

    Eating at resistance hard, looks like this is about to fly. Something's going on today.

    Sentiment: Strong Buy

  • Been following this from afar. Am I to understand the CEO made a planned sale? Then almost immediately afterwards Eisai doubled the sales force for Belviq and the result is a 15% decrease in stock price? Goodness, the doubling of the sales force dwarfs that insider sale in importance for the prospects of this company. I understand the growth of Belviq has been slow, but that's to be expected with a rather tawdry track record for weight reduction products in the past. That will almost certainly change. This appears to be a stock in free fall right now for all the wrong reasons.

  • The CEO 40% sale indicates there is no known bad news on the horizon. Otherwise it would be considered insider trading. Also, Adam Feuerstein's contention this is the death knell for an Eisai buyout is poppycock. If the CEO sale was based on that information he would risking jail time. The sale could actually be indicative of upcoming buyout talks. With Eisai's doubling of the sales force and re-launch of the advertising campaign, they are definitely putting this in the category of "in play". Perhaps the sale was done because there may not be any ability to buy or sell the stock once these talks commence, which would mean the CEO would have to wait for an indefinite period to get access to funds he likely needs in a certain time frame.

1.37+0.02(+1.48%)Sep 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Sky-mobi Limited
NasdaqGMWed, Sep 17, 2014 4:15 PM EDT